JP6652497B2 - 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター - Google Patents

組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター Download PDF

Info

Publication number
JP6652497B2
JP6652497B2 JP2016555659A JP2016555659A JP6652497B2 JP 6652497 B2 JP6652497 B2 JP 6652497B2 JP 2016555659 A JP2016555659 A JP 2016555659A JP 2016555659 A JP2016555659 A JP 2016555659A JP 6652497 B2 JP6652497 B2 JP 6652497B2
Authority
JP
Japan
Prior art keywords
hsv
glycoprotein
virus
vaccine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016555659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510262A (ja
JP2017510262A5 (enExample
Inventor
ジェーコブス、ウィリアム
ゴンサレス・ムノス、パブロ・エイ
ヘロルド、ベッツィ
ペトロ、クリストファー
Original Assignee
アルバート アインシュタイン カレッジ オブ メディシン
アルバート アインシュタイン カレッジ オブ メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルバート アインシュタイン カレッジ オブ メディシン, アルバート アインシュタイン カレッジ オブ メディシン filed Critical アルバート アインシュタイン カレッジ オブ メディシン
Publication of JP2017510262A publication Critical patent/JP2017510262A/ja
Publication of JP2017510262A5 publication Critical patent/JP2017510262A5/ja
Application granted granted Critical
Publication of JP6652497B2 publication Critical patent/JP6652497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016555659A 2014-03-03 2015-03-02 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター Active JP6652497B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461946965P 2014-03-03 2014-03-03
US61/946,965 2014-03-03
US201462080663P 2014-11-17 2014-11-17
US62/080,663 2014-11-17
PCT/US2015/018272 WO2015134368A2 (en) 2014-03-03 2015-03-02 Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020009043A Division JP6844045B2 (ja) 2014-03-03 2020-01-23 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター

Publications (3)

Publication Number Publication Date
JP2017510262A JP2017510262A (ja) 2017-04-13
JP2017510262A5 JP2017510262A5 (enExample) 2018-04-12
JP6652497B2 true JP6652497B2 (ja) 2020-02-26

Family

ID=54055977

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016555659A Active JP6652497B2 (ja) 2014-03-03 2015-03-02 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター
JP2020009043A Active JP6844045B2 (ja) 2014-03-03 2020-01-23 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター
JP2021026943A Active JP7050193B2 (ja) 2014-03-03 2021-02-24 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020009043A Active JP6844045B2 (ja) 2014-03-03 2020-01-23 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター
JP2021026943A Active JP7050193B2 (ja) 2014-03-03 2021-02-24 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター

Country Status (6)

Country Link
US (5) US9999665B2 (enExample)
EP (2) EP3113801B1 (enExample)
JP (3) JP6652497B2 (enExample)
CN (2) CN106456805B (enExample)
AU (2) AU2015225499B2 (enExample)
WO (1) WO2015134368A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
US10918712B2 (en) * 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
MX2020011257A (es) 2018-04-27 2021-01-15 Krystal Biotech Inc Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
WO2019213305A1 (en) * 2018-05-01 2019-11-07 Albert Einstein College Of Medicine HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE
WO2020056411A1 (en) * 2018-09-14 2020-03-19 Excell Biotech, Llc Recombinant herpes simplex virus 1 (hsv-1)
EP3856914A1 (en) 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
JP2022512747A (ja) * 2018-10-17 2022-02-07 アルベルト・アインシュタイン・カレッジ・オブ・メディシン 抗体依存性細胞傷害（ａｄｃｃ）を増強する方法
KR20240116556A (ko) * 2019-01-03 2024-07-29 앨버트 아인슈타인 컬리지 오브 메디신 재조합 단순 헤르페스 바이러스 2 (hsv-2) 백신 벡터를 사용한 면역의 수동 전달
WO2021207348A1 (en) * 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd
IL298288B2 (en) * 2020-05-29 2025-03-01 Albert Einstein College Medicine Methods for using Delta-gD of single-stranded HSV-2 virus and recombinant HSV-2 glycoprotein D
US11987805B2 (en) 2020-09-24 2024-05-21 Albert Einstein College Of Medicine Attb cell line, transgenic cell lines derived therefrom, and methods of making the same
WO2023245159A1 (en) * 2022-06-16 2023-12-21 Albert Einstein College Of Medicine Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines
AU2023319760A1 (en) * 2022-08-05 2025-02-13 Immvira Co., Limited Replication incompetent herpes simplex virus type 1 viral vaccine
US20250222112A1 (en) * 2022-10-14 2025-07-10 Arizona Board Of Regents On Behalf Of Arizona State University Recombinant immune complexes targeting herpes simplex virus
WO2025231288A2 (en) 2024-05-01 2025-11-06 Viradigm, Inc. Hsv vectors having improved safety profiles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT77014B (en) * 1982-07-20 1986-01-24 Molecular Genetics Inc Production of herpes simplex viral proteins
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
EP0231209B1 (en) * 1985-07-29 1991-02-06 The Upjohn Company Virus vaccine
US5646041A (en) * 1987-02-12 1997-07-08 Harfeldt; Elisabeth Monoclonal antibody to herpes simplex virus and cell line producing same
EP0689603A1 (en) * 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
US20030083289A1 (en) * 1995-10-19 2003-05-01 Boursnell Michael Edward Griffith Herpesvirus vectors and their uses
CN1120238C (zh) * 1998-05-04 2003-09-03 本元正阳基因技术股份有限公司 以粘粒为基础构建重组单纯疱疹病毒及其用途
EP1238086B1 (en) 1999-12-17 2006-03-08 Wyeth Holdings Corporation Vaccine for enhancing immune responses to herpes simplex virus
WO2005005637A2 (en) * 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
US20080089910A1 (en) 2004-06-29 2008-04-17 Visalli Et Al Attenuated Herpes Simplex Virus Type-2, Vectors Thereof and Immunogenic Compositions Thereof
JP2008507784A (ja) 2004-07-26 2008-03-13 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 実行可能医療ガイドラインの実行をシミュレートするための意思決定支援システム
US8865185B2 (en) * 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
EP2059255A4 (en) * 2006-09-08 2011-08-31 Univ Pennsylvania HSV-1 AND HSV-2 VACCINES AND METHOD FOR THEIR USE
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2009089154A2 (en) * 2008-01-03 2009-07-16 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
CN101288770A (zh) * 2008-03-14 2008-10-22 浙江省医学科学院 新型单纯疱疹病毒ⅱ型dna疫苗
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
WO2011035004A1 (en) * 2009-09-18 2011-03-24 Fraunhofer Usa Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
CN106456805B (zh) * 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

Also Published As

Publication number Publication date
AU2015225499A1 (en) 2016-10-20
EP3943106A1 (en) 2022-01-26
AU2020217310A1 (en) 2020-08-27
US10980874B2 (en) 2021-04-20
CN106456805A (zh) 2017-02-22
US20170202952A1 (en) 2017-07-20
US20190111127A1 (en) 2019-04-18
JP2017510262A (ja) 2017-04-13
JP2020079245A (ja) 2020-05-28
CA2942166A1 (en) 2015-09-11
JP6844045B2 (ja) 2021-03-17
US10076568B2 (en) 2018-09-18
CN110938604B (zh) 2024-04-05
AU2020217310B2 (en) 2023-07-13
CN110938604A (zh) 2020-03-31
US10391165B2 (en) 2019-08-27
US20160158343A1 (en) 2016-06-09
AU2015225499B2 (en) 2020-05-14
EP3113801A4 (en) 2017-10-25
JP7050193B2 (ja) 2022-04-07
US20200023058A1 (en) 2020-01-23
EP3113801A2 (en) 2017-01-11
WO2015134368A2 (en) 2015-09-11
JP2021088590A (ja) 2021-06-10
US10751411B2 (en) 2020-08-25
US9999665B2 (en) 2018-06-19
US20200376114A1 (en) 2020-12-03
EP3113801B1 (en) 2020-10-07
WO2015134368A3 (en) 2015-11-26
CN106456805B (zh) 2020-01-10

Similar Documents

Publication Publication Date Title
JP7050193B2 (ja) 組換え単純ヘルペスウィルス２（ｈｓｖ－２）ワクチンベクター
US10918712B2 (en) Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
JP2024016032A (ja) 組み換え単純ヘルペスウイルス２（ｈｓｖ－２）ワクチンベクターを使用する免疫の受動伝達
AU2019262056A1 (en) HSV-2-delta-gD vaccines and methods for their production and use
US20220088185A1 (en) Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
CA2942166C (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
HK40022690B (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
HK1229721B (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
WO2023245159A1 (en) Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines
HK40022690A (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
HK1229721A1 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200123

R150 Certificate of patent or registration of utility model

Ref document number: 6652497

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250